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We have examined the nature of V3 sequence variability among subtype C human immunodeficiency virus
type 1 (HIV-1) sequences from plasma-derived viral RNA present in infected men from Malawi. Sequence
variability was assessed by direct sequence analysis of the V3 reverse transcription-PCR products, examination
of virus populations by a subtype C V3-specific heteroduplex tracking assay (V3-HTA), and selected sequence
analysis of molecular clones derived from the PCR products. Sequence variability in V3 among the subtype C
viruses was not associated with the presence of basic amino acid substitutions. This observation is in contrast
to that for subtype B HIV-1, where sequence variability is associated with such substitutions, and these
substitutions are determinants of altered coreceptor usage. Evolutionary variants in subtype C V3 sequences,
as defined by the V3-HTA, were not correlated with the CD4 level in the infected person, while such a
correlation was found with subtype B V3 sequences. Viruses were isolated from a subset of the subjects; all
isolates used CCR5 and not CXCR4 as a coreceptor, and none was able to grow in MT-2 cells, a hallmark of
the syncytium-inducing phenotype that is correlated with CXCR4 usage. The overall sequence variability of the
subtype C V3 region was no greater than that of the conserved regions of gp120. This limited sequence
variability was also a feature of subtype B V3 sequences that do not carry the basic amino acid substitutions
associated with altered coreceptor usage. Our results indicate that altered coreceptor usage is rare in subtype
C HIV-1 isolates in sub-Saharan Africa and that sequence variability is not a feature of the V3 region of env
in the absence of altered coreceptor usage.
Human immunodeficiency virus (HIV-1) isolates are phylo-
genetically clustered into distinct groups based on sequence
analysis of the viral genome (reviewed in reference 45). These
groups have been termed subtypes or clades and given alpha-
betical designations (e.g., subtype or clade A). Partial-se-
quence analysis of a portion of a viral genome derived from a
tissue isolate taken in 1959 suggests that the different subtypes
represent a fairly recent radiation (93), perhaps with each
subtype representing the early establishment of independent
focal infections. The major HIV-1 subtype found in the United
States and western Europe, and the most extensively studied
subtype, is subtype B. Subtype C virus is part of an expanding
epidemic in sub-Saharan Africa and India and is now the most
abundant subtype of HIV-1 worldwide (81).
A dramatic feature of subtype B HIV-1 infection is the de
novo evolution of a more pathogenic variant in up to 50% of
infected people (6, 10, 12, 20, 68, 70, 77). This variant repre-
sents an altered form of the virus whose appearance corre-
sponds to an accelerated decrease in the number of circulating
CD41 T helper cells (42, 69). Typically, transmitted virus uses
the CCR5 chemokine receptor as a coreceptor for entry into
cells (3, 16, 26, 31, 32) and has also been characterized as
nonsyncytium inducing (NSI), slow/low, and macrophage
tropic (65, 84, 94); this type of virus has been named R5 (8).
The new variant that has evolved from the initial R5 virus is
able to use an alternate chemokine receptor, typically CXCR4
(36), and has been characterized as syncytium inducing (SI),
rapid/high, and T-cell-line tropic (reviewed in reference 7).
Variants that use CXCR4 are now called X4 (8). Primary X4
isolates can be dually tropic for CXCR4 and CCR5 (73).
Sequence alignments of the env gene revealed multiple vari-
able regions (2, 76, 86), which were subsequently named V1 to
V5 (57). The major determinant of specificity in coreceptor
usage by subtype B isolates is within the V3 loop domain of the
viral Env protein (16, 17, 75; reviewed in reference 71). Se-
quence changes within V3 are largely responsible for deter-
mining coreceptor specificity, probably through a direct inter-
action with surface residues of the chemokine receptor (9, 17,
79, 88).
There are distinctive sequence changes in V3 that are asso-
ciated with the change in coreceptor usage. These changes
include substitutions that result in the presence of increased
numbers of basic amino acids at discrete positions within V3
(13, 24, 38, 55, 72). Other changes in the V3 sequence are
strongly associated with the presence of the basic amino acid
substitutions (56), and some of these changes play a direct role
in coreceptor specificity (14). Overall, subtype B V3 sequences
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that contain basic amino acid substitutions display twice as
much amino acid variability from the consensus sequence as do
sequences without the basic amino acids (13, 55). This in-
creased variability is in addition to the basic amino acid sub-
stitutions. The presence of this additional sequence variability
has allowed the heteroduplex tracking assay (HTA) (25) to be
used to rapidly identify V3 evolutionary variants that are
strongly correlated with the more pathogenic (X4) form of the
subtype B HIV-1 (60).
While the evolution of X4 variants among patients infected
with subtype B virus is a striking and well-documented phe-
nomenon, its impact on people infected with viruses of other
subtypes is not known. Viruses that use the CXCR4 receptor
(SI phenotype) have been identified among most of the HIV-1
subtypes (23, 28, 63, 80, 89–92). In cases where the X4 viruses
of other subtypes have been examined, these variants encode
increased numbers of basic amino acids in their V3 loops (23,
28, 63, 89, 92), suggesting that common mechanisms are de-
termining changes in coreceptor interactions. However, the
potential for differences in patterns of coreceptor usage among
the different subtypes was suggested by the observation that
subtype C SI/X4 variants were rare among a group of 16
people under care in Sweden (80) and among a group of 22
French military personnel infected during overseas deploy-
ment (63), although subtype C SI/X4 variants have been ob-
served (78, 80, 91).
Understanding the differences in the evolution of subtype C
virus is becoming increasingly important because the domi-
nance of this subtype in the worldwide HIV epidemic will lead
to the inevitable expansion of subtype C vaccine development.
Because of our ongoing clinical studies in Malawi (18, 33), we
had an opportunity to examine this question in a study of a
large cohort of men infected primarily with subtype C HIV-1.
We adapted the V3-HTA (60) to detect V3 evolutionary
variants of subtype C virus. In a group of plasma samples from
80 HIV-1-infected men from Malawi, we found that 31% of
the samples showed evidence of evolutionary variants within
the V3 region. However, the presence of these variants was not
related to low levels of CD41 T cells, as is seen in people
infected with subtype B HIV-1. Sequence analysis of viral
RNA revealed a virtual absence of basic amino acid substitu-
tions in the V3 regions of the evolutionary variants. Virus
isolates were established from a subset of the Malawi subjects,
and all of them preferentially used the CCR5 receptor for virus
entry. Total sequence variability in subtype C V3 sequences
was comparable to the reduced variability seen with sequences
from subtype B viruses that do not contain basic amino acid
substitutions in the V3 loop and was similar in magnitude to
the variability in the conserved regions of env. These results
indicate that X4 variants are rare among men in sub-Saharan
Africa infected with subtype C virus and that V3 variability is
a feature of viruses with altered coreceptor usage.
MATERIALS AND METHODS
Source of patient samples. Plasma and peripheral blood mononuclear cells
(PBMC) were collected and processed from subjects in the sexually transmitted
disease and dermatology clinics of the Lilongwe Central Hospital in Lilongwe,
Malawi, as described previously (18). HIV-1 seropositivity was determined by
two enzyme immunoassays (Genetic Systems HIV-1/HIV-2 EIA; Genetics Sys-
tems Corp., Redmond, Wash.; and Murex HIV-112; Murex Diagnostics Ltd.,
Dartford, United Kingdom) and Western blot analysis (Organon-Teknika,
Durham, N.C.), after which the HIV-1 serotype was determined by an envelope
V3 peptide immunoassay with antigens specific for clades A through F (33, 62).
Plasma samples from subjects infected with HIV-1 subtype B were chosen from
the samples that were collected as part of AIDS Clinical Trial Group Clinical
Trial 201 (37) with Institutional Review Board approval. Subtype B samples were
chosen from subjects with fewer than 400 CD41 T cells/ml.
Virus isolation and test for coreceptor usage. The following reagents were
obtained from the National Institutes of Health AIDS Research and Reference
Reagent Program: the MT-2 cell line was from Douglas Richman, the U373-
MAGI cell lines (85) were from Michael Emerman, the YU-2 molecular clone
(51) was from Beatrice Hahn and George Shaw, and the HIV-189.6 viral isolate
(19) was from Ronald Collman. Malcolm Martin provided the AD8 (ADA) (15)
and NL4-3 molecular clones (1), and Nathaniel Landau provided the HIV-1
clone of HXB with the env gene derived from Ba-L (39). PBMC from infected
individuals were cocultured with phytohemagglutinin-stimulated PBMC from
uninfected donors in qualitative HIV cultures as described previously (82). Cul-
ture supernatants were tested twice a week for p24 antigen production (Or-
ganon-Teknika). Virus isolates were assayed in triplicate for syncytium formation
in MT-2 cells by using a previously described method (41). Briefly, 50 ml of
PBMC coculture (including the cells) was added to 5 3 104 MT-2 cells in 150 ml
of medium in a 96-well plate. The cultures were monitored for syncytia twice a
week; they were scored positive when there were three to five syncytia per
high-power field under light microscopy.
Coreceptor usage was determined by using three U373-MAGI cell lines that
express no coreceptor (U373-MAGI), the CCR5 coreceptor (U373-MAGI-
CCR5), or the CXCR4 coreceptor (U373-MAGI-CXCR4) (85). The cell lines
were maintained and infected as described previously (85). Briefly, each of the
cell lines was plated in separate wells of a 48-well plate 1 day prior to infection.
An aliquot of 90 ml of diluted viral supernatant from PBMC coculture was added
to the cells and adsorbed for 2 h at 37°C under 5% CO2. The subtype C viral
isolates were used at a 1:3 dilution in medium or undiluted. Positive control
viruses (YU-2, Ba-L, ADA, NL4-3, and 89.6) in infected-cell supernatants were
used at a 1:6 dilution. An aliquot of 0.5 ml of culture medium was then added to
each well, and the plate was incubated for 40 to 48 h at 37°C under 5% CO2. The
medium was then removed, and the cells were fixed for 5 min with 0.5 ml of fixing
solution (1% formaldehyde, 0.2% glutaraldehyde) per well. The cells were
washed twice with phosphate-buffered saline, 200 ml of staining solution (4 mM
potassium ferricyanide, 4 mM potassium ferricyanide, 2 mM MgCl2, and 0.4 mg
of 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside [X-Gal] per ml in PBS)
was added to each well, and the plate was incubated at 37°C for 2 h. The cells
were then washed with phosphate-buffered saline twice, and the blue cells were
counted.
Viral RNA isolation, RT-PCR, and DNA sequence determination. Viral RNA
was isolated from 140 ml of patient plasma with a QIAamp viral RNA kit
(Qiagen); the RNA was eluted with 50 ml of RNase-free water. Primers for
reverse transcription-PCR (RT-PCR) were designed to correspond to the HIV-1
subtype C V3 consensus sequence present in the Human Retroviruses and AIDS
database (44). The upstream (C1V3) primer was 59-ATAGTACATCTTAATC
AATCTGTAGAAATT-39, and the downstream (C2V3) primer was 59-CCAT
TTATCTTTACTAATGTTACAATGTGC-39; these primers generate a 159-bp
product. RT-PCRs were performed by the method described by Nelson et al.
(60) with the following modifications. RT reaction mixtures of 20 ml consisted of
5 ml of the viral RNA eluate, 13 Expand HF buffer (Boehringer Mannheim), 2.5
mM MgCl2, 1 ml of 10 mM deoxynucleoside triphosphate mix (U.S. Biochemi-
cal), 10 U of RNase inhibitor (Boehringer Mannheim), 15 pmol of primer C-V3,
and 10 U of avian myeloblastosis virus reverse transcriptase (Boehringer Mann-
heim). Reverse transcription was done at 42°C for 30 min, followed by 2 min at
95°C to inactivate the enzyme. A 30-ml aliquot of PCR mix (13 Expand HF
buffer, 2.5 mM MgCl2, 15 pmol of primer C1V3, 2 U of Expand High Fidelity
enzyme mix [Boehringer Mannheim]) was added to each RT reaction mixture.
PCR was carried out in a Stratagene Gradient-40 Robocycler with the following
program: one cycle at 95°C for 2 min 45 s; then 40 cycles at 95°C for 45 s, 49°C
for 45 s, and 68°C for 1 min (after the first 10 cycles, 1 min was added to the 68°C
step for 10 cycles, 2 min was added for the next 10 cycles, and 3 min was added
for the last 10 cycles). RT-PCR of subtype B samples was performed as described
previously (60). The RT-PCR products were purified by using QIAquick PCR
purification columns (Qiagen), and the PCR products were sequenced with an
ABI PRISM dye terminator cycle-sequencing kit (Perkin-Elmer). Alternatively,
the PCR product was cloned into the pT7Blue(R) vector (Novagen), individual
clones were screened by HTA, and examples of each HTA-defined species were
sequenced by using an ABI PRISM dye terminator cycle-sequencing kit.
V3-HTA. Probe construction, probe labeling, and HTA conditions for subtype
C samples were adapted from those described by Nelson et al. (60) and Delwart
et al. (25). Based on direct sequencing of several RT-PCR products, the product
from patient C128 was chosen for probe construction. The C128 RT-PCR prod-
uct was cloned into the pT7Blue(R) vector. Several clones were sequenced, and
a probe plasmid (D516-11) was chosen that had only three nucleotide differences
from the subtype C V3 consensus. The subtype C V3 probe was labeled by first
digesting 1 mg of D516-11 plasmid with BamHI. The plasmid was end labeled for
15 min at room temperature in a reaction mixture of 50 ml containing 12.5 mCi
of 35S-dATP (1,250 Ci/mmol; NEN Life Science Products), unlabeled dGTP at
final concentration 1 mM, and 2 U of the Klenow fragment of DNA polymerase
I; this was followed by heat inactivation of the enzyme. The plasmid was further
digested with SpeI to release the probe from the vector. The labeled probe was
purified by using a QIAquick PCR purification column and recovered in a final
volume of 50 ml. Heteroduplex formation reactions were done in 10-ml reaction
mixtures consisting of 8 ml of purified RT-PCR product, 1 ml of 103 annealing
buffer (1 M NaCl, 100 mM Tris-HCl [pH 7.5], 20 mM EDTA), 1 mM primer
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C1V3, and 0.8 ml of labeled D516-11 probe. The reaction mixtures were dena-
tured at 95°C for 2 min and allowed to anneal at room temperature for 15 min.
The heteroduplexes were separated in nondenaturing 12% polyacrylamide gels.
V3-HTA of subtype B RT-PCR products was performed as described previously
(60).
A unified linear regression model in rank scale was used to assess the rela-
tionship between the CD4 cell count and the HTA mobility ratio of the samples
with single and multiple bands for both the subtype B and subtype C data sets.
When multiple bands were present, the mobility ratio value of the slowest-
migrating band was used. Calculations were done with SAS (version 6.12) pro-
grams rk0101.sas and rk0102.sas.
Analysis of sequence heterogeneity. Total amino acid variability within the
newly determined V3 sequences was analyzed as follows. The total number of
times a nonconsensus sequence amino acid was present was tallied, this number
was divided by the total number of V3 sequences times 35 (the number of amino
acid positions in V3), and the final number was multiplied by 100 to give the
percentage of amino acid substitutions.
For analysis of evolutionary distance, envelope sequences spanning V1
through V5 were obtained from the Los Alamos HIV-1 database (44). A total of
33 subtype C and 69 subtype B sequences were used. Subtype B sequences were
classified into two groups, either R5-like or X4-like, based on known biological
properties of the viruses or the charge characteristics of amino acids at position
11 or 25 in the V3 loop. Nucleotide sequences from all viruses were aligned by
using DNA (Harvard University Molecular Biology Computer Resources). The
alignments were optimized manually to ensure that codons remained intact and
gaps were minimized (50). Sequences were divided into segments, which ranged
in length from 78 to 150 nucleotides or 26 to 50 codons, based on the location of
hypervariable and conserved domains. Phylogenetic analysis to assess the rela-
tionship among the sequences and between subtype C and subtype B sequences
in V3 was performed by using the neighbor-joining method (66) in the PHYLIP
package (34, 35). Estimation of total distance in each segment among the three
groups of viruses was based on the method of Nei and Gojobori (59) in MEGA
(48). Distances within each segment among the three groups of sequences were
evaluated by a one-way analysis of variance (SigmaStat; Jandel). A pairwise
multiple comparison procedure was used to analyze the significance of relation-
ships between groups (SigmaStat). A P value of ,0.05 was considered significant.
Nucleotide sequence accession numbers. The nucleotide sequences for the V3
region described here have been assigned GenBank accession no. AF153129 to
AF153190.
RESULTS
Application of V3-HTA to subtype C virus. As a starting
point to study the nature of V3 sequence variability in subtype
C virus, we used a collection of plasma samples taken from 80
separate subjects participating in a clinical trial (18, 33). Each
of the samples was taken from an HIV-1-infected subject from
Malawi, and the virus from each subject was characterized as
subtype C by using a V3 peptide immunoassay (33, 62). The
viral RNA level in plasma and CD41-T-cell count for each of
the subjects are presented in Table 1. The range of values for
the CD41-T-cell count was 36 to 1,253 cells/ml, with the me-
dian value being 273 cells/ml; the range of values for viral RNA
load in plasma was 1.6 3 103 by 5,700 3 103 copies/ml.
Subtype C-specific primers were designed based on con-
served regions of subtype C virus sequences in the Human
Retroviruses and AIDS database (44) to amplify a 159-bp
region of the env gene encompassing V3. Initially, RT-PCR
products amplified from viral RNA in plasma from 20 subjects
were analyzed by direct sequencing. Samples that gave largely
unambiguous sequencing results (implying an absence of a
significant mixture of V3 sequences) were used to construct a
consensus V3 sequence for subtype C.
A clone from the RT-PCR product derived from the plasma
of subject C128 was chosen for the V3-HTA probe because it
was the closest to the consensus sequence; it varies from the
consensus sequence at only three widely spaced positions, and
all three of the differences are G-to-A transitions. The probe
was labeled by first cleaving the V3 insert at one junction with
the plasmid by using a unique restriction enzyme site in the
plasmid. The overhanging end was filled in with a radioactive
nucleotide to label one strand of the probe, allowing detection
of heteroduplexes formed with only one of the probe strands.
The probe insert was then released from the plasmid by cleav-
age at a second unique cleavage site at the other insert/plasmid
junction. The inclusion of several flanking nucleotides from the
plasmid in the probe results in distinct migrations for the
reannealed probe strands versus the heteroduplexes formed
between the labeled probe strand and complementary RT-
PCR products (60).
Characterization of viral RNA in plasma by V3-HTA. V3-
HTA is able to identify many sequence variants within the
region of env encoding V3 (60). The magnitude of sequence
evolution that leads to a change in coreceptor usage is, in most
cases, significant enough to score in the V3-HTA. Such se-
quence variants cause the heteroduplex formed between the
PCR product and the probe to bend and therefore to be re-
tarded during polyacrylamide gel electrophoresis. As a first
step in characterizing subtype C V3 sequence variability, we
applied this assay to the RT-PCR product from each of the 80
plasma samples. Such an analysis provides two pieces of infor-
mation: first, the presence of variants with sequences distinct
from the probe can be identified; second, the presence of
mixtures of cocirculating viral sequences is revealed. Examples
of V3-HTA patterns from subjects with homogeneous V3 se-
quences (single band) or heterogeneous V3 sequences (multi-
ple bands) are shown in Fig. 1. A summary of the V3-HTA
results for the plasma samples is shown in Table 1.
Of the 80 plasma samples, 55 had single bands in the V3-
HTA analysis, indicating that the virus populations in these
samples were homogeneous within V3. The remaining 25 sam-
ples had multiple bands in the V3-HTA analysis, revealing the
presence of multiple virus species with different V3 sequences.
Of the samples with single bands, 53 had bands that migrated
near the bottom of the gel, indicating similarity to the consen-
sus sequence. The other two samples (S018 and S051) had
single bands that migrated more slowly, indicative of significant
sequence differences with respect to the probe (Table 1). Se-
quence analysis of the bulk PCR product was done for 46 of
the samples that gave a single band in V3-HTA and for 7
samples that gave multiple bands but for which there was a
predominant band with rapid mobility and unambiguous se-
quence. In addition, seven samples that gave multiple bands
were subjected to molecular cloning, and individual clones
were screened by V3-HTA and sequenced. In total, sequence
information was determined for 62 of the 80 samples.
We previously found a strong correlation between subtype B
HIV-1 samples that had slowly migrating bands in the V3-HTA
analysis, the presence of sequence changes that would encode
basic amino acid substitutions in the V3 loop, and the presence
of SI viruses in the virus isolate (60). Therefore, we were
interested in determining the nature of the sequence changes
in the subtype C isolates that resulted in slow migration in the
V3-HTA analysis. A summary of the amino acid substitutions
encoded by the nucleotide changes for the shifted bands rep-
resenting viruses from nine patients is shown in Fig. 2. This
includes the two samples that had a single band with low
mobility (S018 and S051) and seven of the samples with mul-
tiple bands. Bands were considered “shifted up” if the mobility
ratio (the distance migrated by the heteroduplex divided by the
distance migrated by the probe homoduplex) was less than
0.85, and by this definition only 10 of the samples with multiple
bands included bands that were considered significantly
shifted. Seven of the nine sequenced examples of shifted bands
were due to three nucleotide deletions, usually corresponding
to position 24 or 25 of V3. One of the sequences with a
deletion (S031) and one other sequence (S134) had basic
amino acid substitutions that are associated with the SI/X4
phenotype in subtype B viruses. The ninth sequence, C034,
shifted because of clustered mutations away from the consen-
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sus, but these did not include basic amino acid substitutions.
These results suggest that clustered mutations that include
basic amino acid substitutions, which are characteristic fea-
tures of subtype B X4 variants, are not a prominent feature of
V3 sequence variability among subtype C sequences.
Comparison of evolutionary variants in subtype B and sub-
type C. X4 viruses typically evolve late in the course of an
HIV-1 infection, usually when the levels of CD41 T helper
cells fall below 400/ml (42). We carried out an analysis of the
appearance of evolutionary variants among subtype B versus
subtype C HIV-1 as a function of the patient CD41-T-helper-
cell level (Fig. 3). Samples were obtained from subjects in-
fected with subtype B virus who were participants in an ACTG
study. As expected, among the subtype B viruses, V3-HTA
(with the subtype B probe) revealed slowly migrating bands
and/or multiple bands with increasing frequency as patient
CD41-T-helper-cell levels declined. In contrast, the presence
of slowly migrating bands derived from the subtype C viruses
(detected with the subtype C probe) showed no relationship
with the patient CD41-T-helper-cell level. The association was
tested by using a unified linear-regression model in rank scale
(n 5 83). The subtype B samples with multiple bands showed
an association between decreasing mobility ratio and decreas-
ing CD4 counts that approached statistical significance even
with this small sample size (slope 5 0.462; P 5 0.06). This was
not the case for the subtype B samples with single bands
(slope 5 0.158; P 5 0.35) or the subtype C samples with either
multiple bands (slope 5 0.011; P 5 0.94) or single bands
(slope 5 0.006; P 5 0.96). Thus, there appears to be a differ-
ence between these two subtypes in the nature of V3 sequence
variants as detected by V3-HTA. The difference was tested
statistically by a comparison of slopes (0.426 versus 0.011; P 5
0.13). A plausible explanation for the lack of statistical signif-
icance is the small sample size for subtype B (n 5 26). The
power of the test comparing slopes was approximately 0.324, or
32.4%.
Coreceptor usage of subtype C viruses. Both the near ab-
sence of basic amino acid substitutions in samples scoring in















C128 220 159 0.95 S067 160 ND 0.92
C044 150 92 0.95 S088 130 569 0.92
C120* 1,000 268 0.95 S100 150 210 0.92
S007* 49 273 0.95 S147 470 188 0.92
S036 110 631 0.95 S173 15 36 0.92
S059 1,300 259 0.95 C054 260 190 0.91
S080* 850 212 0.95 S005 720 29% 0.91
S103* 190 454 0.95 S071 65 81 0.91
S111 17 NDd 0.95 C087 470 284 0.90
S115 460 36 0.95 S081 35 101 0.90
S116 220 628 0.95 S171 180 441 0.90
S200 5,700 132 0.95 S048 58 334 0.89
C012* 380 863 0.94 S002 10,000 41% 0.88
C040 1.9 152 0.94 S051 29 1,253 0.79
C065 260 171 0.94 S018* 580 476 0.69
C070 270 172 0.94 C102 87 560 0.93/0.95
C096 320 350 0.94 S083* 810 166 0.92/0.95
C109 62 328 0.94 S158 38 348 0.92/0.95
S003* 240 21% 0.94 S101 610 235 0.92/0.94
S017* 590 178 0.94 S122 ND 359 0.92/0.94
S021* 48 154 0.94 S094 280 101 0.91/0.95
S119 530 364 0.94 S077 63 153 0.90/0.95
S146 380 258 0.94 C022 210 54 0.90/0.94
S148 66 344 0.94 S176 ND 314 0.90/0.93
S166 48 274 0.94 C007* 78 190 0.90/0.92
S172 63 344 0.94 S009* 220 122 0.89/0.91
C011* 540 67 0.93 S040 17 480 0.88/0.91
C019 1,000 599 0.93 S141 18 115 0.88/0.90
C047 140 291 0.93 S191* 640 187 0.87/0.91
C113 360 279 0.93 C018* 490 116 0.87/0.89/0.91
S047* 760 469 0.93 S134 340 534 0.83/0.87/0.91
S053 630 318 0.93 C034 3,300 268 0.81/0.88/0.91
S070 55 670 0.93 C030 580 322 0.80/0.95
S084* 10 248 0.93 S073 32 275 0.78/0.95
S128 140 11% 0.93 S123 590 399 0.78/0.92/0.94
S159 430 98 0.93 C061 360 262 0.78/0.83/0.87
S174 170 529 0.93 C111 69 210 0.77/0.79/0.88
S194 130 322 0.93 S206 350 168 0.76/0.90/0.92
C045 710 479 0.92 S180 170 37 0.74/0.93
S032 1.6 881 0.92 S031* 43 333 0.62/0.73/0.74/0.84
a Samples for which a virus isolate was recovered are indicated by asterisks.
b CD41-T-cell count per microliter or percentage of CD41 T cells among all T cells.
c Mobility ratios are shown for all heteroduplexes in each sample.
d ND, not determined.
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the V3-HTA analysis and the lack of correlation between V3
sequence variants and CD41-T-helper-cell levels suggested
that subtype C viruses do not evolve to utilize different core-
ceptors in a manner analogous to that seen with subtype B
viruses. To determine the nature of coreceptor usage among
these viruses, PBMC corresponding to 79 of the 80 plasma
samples were used in coculture assays to recover virus. Virus
isolates were obtained from only 19 of the 79 samples. Four-
teen of these isolates were from patients with less than 400
CD41 T cells/ml, the point at which X4 viruses start appearing
in people infected with subtype B viruses (42). The isolates
were tested for coreceptor usage in U373-MAGI cell lines (85)
and for syncytium induction in MT-2 cells, a frequent feature
of subtype B X4 variants (43). As shown in Table 2, all of the
isolates used CCR5 as a coreceptor, did not use CXCR4, and
did not induce syncytia in MT-2 cells. An additional 12 subtype
C isolates that were not associated with the 80 plasma samples
were tested in the MT-2 assay, and all were NSI (data not
shown), although this additional group has not been subjected
to sequence, V3-HTA, or coreceptor usage analysis. To date
we have not found a single example of CXCR4 coreceptor
usage or SI phenotype among the 31 subtype C virus isolates in
our collection.
Analysis of V3 sequence variability in subtype C HIV-1. We
combined the sequence data from the 62 samples analyzed in
this study with 64 sequences available for subtype C viruses in
the Human Retroviruses and AIDS database (44) to create a
data set that would allow an estimate of total sequence vari-
ability within V3. Five subtype C sequences that had deletions
were removed from the data set and not included in this anal-
ysis, leaving 121 sequences. Each deletion was of 3 nucleotides,
i.e., one codon, and appeared at position 24 or 25, suggesting
that these are positions that can accommodate a deletion.
These deletions do not appear to be involved in altered core-
ceptor usage, since three of the viruses with these deletions
were included in the analysis of coreceptor usage and all were
specific for CCR5 (Fig. 2, Table 2).
The pattern of sequence variability for subtype C, as shown
in Fig. 4, was compared to the patterns of sequence variability
seen in the two sets of subtype B viruses, those without basic
amino acid substitutions (NSI/R5-like) and those with basic
amino acid substitutions (SI/X4-like) (56). We previously
noted that NSI/R5-like sequences, presumed to represent R5
variants, have half as much sequence variability as do SI/X4-
like sequences, presumed to represent X4 variants (56), and
this pattern can be seen in Fig. 4. Total sequence variability
among the subtype C viruses was nearly identical to that of the
NSI/R5-like V3 loop sequences of the subtype B viruses and
was approximately one-half of the variability of the subtype B
viruses with SI/X4-like V3 loop sequences. Also, there was a
virtual absence of nonconservative basic amino acid substitu-
tions among subtype C sequences, with single examples at
positions 11 and 25, the two positions most commonly substi-
tuted with a basic amino acid among subtype B sequences.
There are five amino acid positions within V3 where the
subtype C consensus sequence differs substantially from the
subtype B consensus sequence: positions 13, 18, 19, 22, and 25.
FIG. 1. Examples of V3-HTA patterns obtained with the subtype C probe.
RT-PCR products were generated from viral RNA isolated from the plasma of
subjects infected with HIV-1 subtype C. Lanes: 1, probe without PCR product;
2, probe with PCR product generated from the D516-11 probe plasmid; 3 to 18,
examples of RT-PCR products from subjects with either a single dominant
heteroduplex band or multiple heteroduplex bands. Starting with lane 3, the
order is as follows: S115, C011, S081, C044, S071, S200, S021, C065, S180, C111,
C034, S073, S031, S123, S134, and S191. The positions in the gel of the single-
stranded probe (A), probe homoduplex (B), and heteroduplexes with the most
rapid migration (C) are shown.
FIG. 2. Alignment of inferred V3 amino acid sequences corresponding to V3-HTA bands with mobility ratios of less than 0.85. Each sequence represents a single
clone from the RT-PCR product from that subject. The mobility of each clone was verified by V3-HTA. Basic amino acid substitutions at SI-associated positions are
underlined; deletions are designated by D.
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At position 13, a basic amino acid appears in the subtype C
consensus sequence while a basic amino acid is characteristic
of the X4 variants among subtype B viruses (55). At position
19, threonine is the consensus amino acid in the subtype C
virus, with alanine being a common substitution, while alanine
is the consensus amino acid in the subtype B viruses. Similarly,
at position 22, alanine is the consensus amino acid in the
subtype C viruses while threonine is the consensus amino acid
in the subtype B viruses, with alanine being a frequent substi-
tution. In these last two cases, a pair of amino acids is allowed
in one subtype while one of these is essentially fixed in the
other subtype. Although the consensus amino acid at position
25 is different in these two subtypes, in both cases it is an acidic
amino acid with both acidic amino acids being frequently rep-
resented in both viruses. Finally, the glutamine at position 18
represents the common amino acid at this position outside of
the subtype B viruses (44).
Is V3 really variable? The original description of five vari-
able regions flanked by conserved regions in the env gene was
based on sequence comparisons of subtype B viruses that in-
cluded R5-like and X4-like sequences (57). We considered the
possibility that the excess variability in V3 is either the result of
or associated with change in coreceptor usage. To determine
the level of V3 variability in the absence of altered coreceptor
use, we compared a collection of subtype C env sequences to a
group of subtype B env sequences that were sorted into R5-like
and X4-like groups by using a conservative criterion based on
the presence or absence of a basic amino acid substitution at
either position 11 or position 25. Between 30 and 39 env se-
quences spanning V1 through V5 were available for each
group from the Los Alamos HIV-1 sequence database (44).
The length of each sequence was divided into segments of 26
to 50 codons, representing discrete variable and conserved
regions, and the evolutionary distance for each segment was
determined. The distances between the groups of viral se-
quences within each segment and between segments were com-
pared. The results are shown in Fig. 5. As expected, the V3
region of the X4-like subtype B sequences is more variable
than the V3 region of the subtype B R5-like sequences (P ,
0.01). The V3 region of subtype C sequences is similar in its
variability to the R5-like sequences of subtype B and less
variable than the subtype B X4-like sequences (P , 0.05).
Finally, while the V3 domain of the subtype B X4-like se-
quences is more variable than the flanking conserved domains
(P , 0.01), the V3 regions of both the subtype B R5-like
sequences and the subtype C V3 sequences are no more vari-
FIG. 3. V3-HTA mobility ratios plotted against the CD41-T-cell count. Only the lowest mobility ratio was used for samples with multiple bands. The data for the
subtype C viruses were taken from Table 1. The data from the subtype B viruses were generated from samples described in Materials and Methods.
TABLE 2. Coreceptor usage determined by a U373-MAGI
assay of viral isolates
Isolate








YU2 2 132 10 13 CCR5 NDb
BAL 3 301 53 5.7 CCR5 ND
AD8 1 153 15 10 CCR5 ND
89.6 2 934 1,482 0.6 CCR5/CXCR4 ND
NL43 2 1 598 0.0017 CXCR4 1
C007 1 58 2 29 CCR5 2
C011 1 69 8 8.6 CCR5 2
C012 0 227 10 23 CCR5 2
C018 3 569 21 27 CCR5 2
C120 2 66 5 13 CCR5 2
S003 2 592 23 26 CCR5 2
S007 2 147 4 37 CCR5 2
S009 6 364 22 17 CCR5 2
S017 4 143 15 9.5 CCR5 2
S018 6 83 9 9.2 CCR5 2
S021 10 67 8 8.4 CCR5 2
S031 6 95 5 19 CCR5 2
S047 4 24 2 12 CCR5 2
S080 16 67 16 4.2 CCR5 2
S083 1 26 2 13 CCR5 2
S084 8 524 31 17 CCR5 2
S103 6 213 34 6.3 CCR5 2
S180 1 76 9 8.4 CCR5 2
S191 3 23 3 7.7 CCR5 2
a Assays were done in duplicate; the value given is the average from two wells.
U, U373-MAGI; U-CCR5, U373-MAGI-CCR5; U-CXCR4, U373-MAGI-
CXCR4.
b ND, not determined.
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able than the flanking conserved regions. Thus, in the absence
of sequence changes associated with change in coreceptor use
(i.e., X4 viruses), the V3 domain is no more variable than the
conserved regions of env.
We extended the analysis of the extent of sequence variabil-
ity between the groups of sequences to the other regions of env.
With the exception of V4, each group of viral sequences (sub-
type C, subtype B X4-like, and subtype B R5-like) showed
comparable levels of variability within each segment that was
compared, including both the variable and conserved regions.
However, within the V4 region, the subtype C sequences were
significantly more variable than the comparable sequences
from subtype B. A previous analysis of small regions immedi-
ately flanking V3 also found comparable levels of sequence
variability among different subtypes (29). Thus, it is not the
case that overall subtype C env genes are less divergent but,
rather, that V3 is not more divergent.
DISCUSSION
In up to 50% of people infected with subtype B HIV-1, a
distinctive variant of the virus evolves with the ability to use an
alternative coreceptor. We have used five criteria to evaluate
the presence of equivalent variants among subtype C HIV-1.
Based on the results of experiments examining all five criteria,
we conclude that X4 variants of HIV-1 are rare among subtype
C viruses, in contrast to their frequent appearance among
subtype B viruses. First, basic amino acid substitutions were
rare among a large collection of V3 sequences from subtype C
viruses (Fig. 2 and 4). Such substitutions are the hallmark of
X4 variants among subtype B viruses (13, 24, 38, 55, 72).
Second, total sequence variability among subtype C V3 se-
quences was low, comparable to the V3 variability of sequences
representative of subtype B R5 variants and lower than the V3
variability of sequences representative of X4 variants (Fig. 4
and 5). The absence of the variability in subtype C sequences
that would be associated with X4 variants probably explains, at
least in part, the previous observation that subtype C V3 se-
quences are more highly conserved than in other subtypes (29,
46). Third, there was a lack of correlation between the appear-
ance of multiple V3 sequence variants and more extensive V3
sequence evolution as a function of decreasing CD41-T-help-
er-cell levels (Fig. 3). Such a correlation is seen with subtype B
viruses (Fig. 3), and the appearance of multiple divergent V3
species is correlated with the presence of SI variants (60).
Fourth, when a subset (19 of 80) of the subtype C viruses were
isolated by culture of primary PBMC, none of the viral isolates
was able to form syncytia in MT-2 cells (Table 2); replication in
transformed T-cell lines is another feature of SI/X4 variants
(43). Fifth, a direct test of coreceptor usage demonstrated that
these isolates preferentially used CCR5 and had not evolved to
use CXCR4 for entry (Table 2). Thus, by all five criteria,
subtype C viruses appear to be predominantly R5 variants of
HIV-1 with, by comparison to subtype B HIV-1, a significant
underrepresentation of X4 variants. X4 variants among differ-
ent subtypes appear to select basic amino acid substitutions in
V3 as a generalizable strategy for evolving to use CXCR4 as a
coreceptor (23, 28, 63, 89, 92). Why, then, is evolution to use
CXCR4 not a prominent feature of infection with subtype C
HIV-1?
There is as yet too little information to answer this question,
but there is a range of possibilities that can be considered.
Although subtype C viruses can evolve to use CXCR4, perhaps
the ability of a subtype C Env protein to accommodate the
required amino acid changes is lower than that of a subtype B
Env protein. Given the ability of HIV-1 to evolve, this possi-
bility seems unlikely but remains unproved. The detection of at
least some SI/X4 variants with a subtype C Env (78, 80, 91)
demonstrates that there is no absolute block to the evolution of
these variants. Another possibility is that subtype C viruses
have not had sufficient time to evolve into X4 variants. HIV-
1-infected people in developing countries can go through a
more rapid disease course (5). X4 variants generally appear
after a number of years of infection with a subtype B virus,
typically when levels of CD41 T helper cells are below 400/ml.
Therefore, a shorter disease course in people living in devel-
FIG. 5. Evolutionary distances of segments of gp120. Groups of sequences of the gp120 coding region for subtype C, subtype B R5-like, and subtype B X4-like
viruses were assembled from the Los Alamos HIV-1 Sequence Database. A description of the sequences used is available on request. The sequences were aligned and
then divided into segments of between 26 and 50 codons. These segments are indicated in the figure below the line, using the HIV-1JR-FL numbering. The region in
C3 just downstream of V3 was omitted because of its recently described position as an external loop (loop E) in the protein structure with associated sequence variability
(49). Evolutionary distance was calculated for each segment for each group of sequences. The distance of each segment within a group was compared to the equivalent
distance in the other two groups to determine if they were significantly different. The two cases where a statistically significant difference was observed are noted with
an asterisk. The vertical thin lines show standard error.
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oping countries may preclude X4 variants from appearing. A
corollary of this scenario is the possibility that the evolution of
X4 variants is comparable to the appearance of an opportu-
nistic infection. However, if one succumbs to an initial oppor-
tunistic infection, subsequent opportunistic infections are pre-
cluded. The lack of linkage between low CD41-T-helper-cell
levels and the presence of V3 sequences characteristic of X4
variants suggests that it is not the absence of a longer disease
course that precludes the appearance of subtype C X4 variants.
One limitation of our study is that our subject population
consisted of relatively healthy persons, although they did have
a wide range of CD41-T-helper-cell levels (Table 1). Also, it is
clear that other subtypes, for example subtype D, are readily
evolving SI/X4 variants in a similar population (reviewed in
reference 29).
Several genetic polymorphisms affect the disease course and
the evolution of SI/X4 virus in people infected with HIV-1. A
deletion in the CCR5 gene (22, 27, 40, 52, 54, 67) and a genetic
polymorphism in the CCR2 gene (4, 47, 64, 74, 83) have been
associated with slowed disease progression in infected people,
although it has been suggested that the CCR2 effect occurs
predominantly in people of African descent (58). The absence
of these allelic variants in a given population might increase
the apparent rate of disease progression and perhaps influence
the frequency of SI/X4 evolution. The CCR5 mutation is rare
among African-American and African populations (22, 52, 53,
67), but the CCR2 polymorphism is common (4, 74), and its
presence contrasts with the more rapid disease progression
that is a feature of HIV-1 infection in sub-Saharan Africa (5).
These mutations also select for an increased incidence of SI/X4
variants (21, 83), again in contrast to what is observed in the
Malawi cohort. An allelic variant of the SDF-1 gene has been
reported to reduce HIV-1 disease progression, perhaps
through elevated levels of SDF-1 that protect against SI/X4
variants, but this allele is not common, at least among African-
Americans (87), although the opposite effect has also been
reported (58). Thus, the near absence of SI/X4 variants among
the cohort of men in Malawi infected with subtype C HIV-1
cannot easily be ascribed to known genetic variation in the host
population.
The reduced variability of R5-like viral sequences prompted
the question whether this represented significant variability
within the env gene (Fig. 5). We found that V3 in the absence
of the sequence variability associated with changes in corecep-
tor use is no more variable than the conserved regions of
gp120. V3 variability among X4-like viral sequences is about
twice that among R5 sequences (13, 55). Half of this variability
is linked to the presence of basic amino acid substitutions, and
another quarter of the variability is represented by another set
of substitutions that are biased in their presence in X4-like
viral sequences (56). It is not clear what role this additional
variability plays in the biology of the subtype B Env protein,
i.e., whether it plays a direct role in altered coreceptor usage or
whether this variability accumulates for other as yet unknown
reasons that are linked to altered coreceptor usage. Similarly,
simian immunodeficiency virus isolates most often use CCR5
(reviewed in reference 30), and where it has been examined,
V3 is not variable (11, 61).
The lack of coreceptor switching in subtype C virus may
affect transmission. Virus that is transmitted is almost always
CCR5 dependent, regardless of the variants present in the
transmitting donor (65, 84, 94). If the subtype C virus continues
to use the CCR5 coreceptor throughout infection, persons
carrying the subtype C virus may be more infectious through-
out their entire infection than persons carrying subtype B virus
who evolve X4 variants.
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